PAQ Therapeutics Email Format
Biotechnology ResearchMassachusetts, United States11-50 Employees
PAQ Therapeutics is a biotechnology company focused on restoring health by leveraging autophagy, the cell’s intrinsic degradation system. It is developing a new class of small-molecule degraders designed to recruit the autophagy pathway to break down a broad range of substrates, including proteins, aggregates, lipids, organelles, and pathogens. By directing cellular clearance toward disease-relevant targets, the company aims to open a new avenue for therapies and potentially alter how drug discovery and development proceed. The company is based in Burlington, Massachusetts, and operates as a small to mid-sized firm within the biotechnology research sector. It has engaged in collaborations to advance its autophagy-based degradation platform, notably with Insilico Medicine to apply AI-driven discovery to develop these therapies. This focus places PAQ Therapeutics within a growing field seeking to harness autophagy-dependent degradation as a novel drug modality.